Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.46 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16437483 | 1.00 | CHRNB2 (0.46) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL14085972 | 1.00 | CHRNB2 (0.46) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL20782041 | 1.00 | CHRNB2 (0.46) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL11996870 | 1.00 | CHRNB2 (0.46) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL14087022 | 0.86 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL16437475 | 0.81 | CHRNB2 (0.46) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL14085998 | 0.80 | EPHX1 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL22826694 | 0.80 | EPHX1 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL12439047 | 0.80 | EPHX1 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL21375777 | 0.79 | CHRNB2 (0.44) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718841-B2 | Bicyclic pyrazolone compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718841-B2 | Bicyclic pyrazolone compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170183358-A1 | BICYCLIC PYRAZOLONE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170183358-A1 | BICYCLIC PYRAZOLONE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2017-06-29 | — | — | US | disclosed |
| US-9326975-B2 | Substituted pyrazolone compounds and methods of use | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2016-05-03 | — | — | US | disclosed |
| US-20150299219-A1 | BICYCLIC PYRAZOLONE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150141463-A1 | SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | CALITOR SCIENCES, LLC (US) | 2015-05-21 | — | — | US | disclosed |
| US-8975282-B2 | Substituted pyrazolone compounds and methods of use | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-20150037280-A1 | SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150037280-A1 | SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | MKI67, PRKACA, PRKDC | CHRNB2 4734/4885CHRNB4 4656/4885CHRNA3 4744/4885 |
| US-20150141463-A1 | SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | MKI67, PRKACA, PRKDC | CHRNB2 4734/4885CHRNB4 4656/4885CHRNA3 4744/4885 |
| US-20150299219-A1 | BICYCLIC PYRAZOLONE COMPOUNDS AND METHODS OF USE | MET, RET, ERBB2 | CHRNB2 3713/4885CHRNB4 4071/4885CHRNA3 3492/4885 |
| US-20170183358-A1 | BICYCLIC PYRAZOLONE COMPOUNDS AND METHODS OF USE | MET, RET, ERBB2 | CHRNB2 3713/4885CHRNB4 4071/4885CHRNA3 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.